Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Tuttle, Norma Lopez, R. Leboeuf, Shaye Minkowitz, R. Grewal, M. Brokhin, Gal Omry, S. Larson (2010)
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.Thyroid : official journal of the American Thyroid Association, 20 3
David Taïeb, F. Sebag, M. Cherenko, Karine Baumstarck-Barrau, Cécile Fortanier, B. Farman-Ara, C. Micco, Josiane Vaillant, S. Thomas, B. Conte-Devolx, A. Loundou, Pascal Auquier, Jf Henry, Olivier Mundler (2009)
Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled studyClinical Endocrinology, 71
R. Robbins, A. Driedger, J. Magner (2006)
Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.Thyroid : official journal of the American Thyroid Association, 16 11
M Lassmann H Hanscheid (2006)
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalJ Nucl Med: Off Publ, Soc Nucl Med, 47
R. Tuttle, Geneviève Rondeau, N. Lee (2011)
A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer.Cancer control : journal of the Moffitt Cancer Center, 18 2
L. Freudenberg, W. Jentzen, T. Petrich, C. Frömke, R. Marlowe, T. Heusner, W. Brandau, W. Knapp, A. Bockisch (2010)
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisonsEuropean Journal of Nuclear Medicine and Molecular Imaging, 37
(2011)
81st annual meeting of the American Thyroid Association meeting ABSTRACTS & AGENDA
H. Maxon, H. Smith (1990)
Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.Endocrinology and metabolism clinics of North America, 19 3
E. Mazzaferri (2007)
Management of low-risk differentiated thyroid cancer.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 13 5
R. Tuttle, M. Brokhin, Gal Omry, Andrew Martorella, S. Larson, R. Grewal, M. Fleisher, R. Robbins (2008)
Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone WithdrawalJournal of Nuclear Medicine, 49
(2012)
124I PET/CT dosimetric comparisons
H. Maxon, E. Englaro, S. Thomas, Vicki Hertzberg, J. Hinnefeld, L. Chen, H. Smith, D. Cummings, Michael Aden (1992)
Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 33 6
T. Pilli, E. Brianzoni, F. Capoccetti, M. Castagna, S. Fattori, A. Poggiu, G. Rossi, F. Ferretti, E. Guarino, L. Burroni, A. Vattimo, C. Cipri, F. Pacini (2007)
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.The Journal of clinical endocrinology and metabolism, 92 9
I. Hay, G. Thompson, C. Grant, E. Bergstralh, Catherine Dvorak, C. Gorman, Megan Maurer, B. Mciver, B. Mullan, A. Oberg, C. Powell, J. Heerden, J. Goellner (2002)
Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated PatientsWorld Journal of Surgery, 26
A. Rudavsky, L. Freeman (1997)
Treatment of Scan-Negative, Thyroglobulin-Positive Metastatic Thyroid Cancer Using Radioiodine 131I and Recombinant Human Thyroid Stimulating HormoneThe Journal of Clinical Endocrinology and Metabolism, 82
SM Larson RJ Robbins (2002)
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablationJ Nucl Med: Off Publ, Soc Nucl Med, 43
Chao Ma, Jiawei Xie, Wanxia Liu, Guoming Wang, S. Zuo, Xufu Wang, Fengyu Wu (2010)
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.The Cochrane database of systematic reviews, 11
http (2010)
//www.itc2010.com/download/ITC2010_programme.pdf
M. Gapany (2012)
Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancerYearbook of Otolaryngology-head and Neck Surgery, 2012
M. Chianelli, V. Todino, F. Graziano, C. Panunzi, D. Pace, R. Guglielmi, A. Signore, E. Papini (2009)
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.European journal of endocrinology, 160 3
B. Depczynski, S. Lillioja, A. Driedger (2004)
Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.The Journal of clinical endocrinology and metabolism, 89 2
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J. Travagli, B. Caillou, M. Ricard, J. Lumbroso, F. Vathaire, M. Schlumberger (2006)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.The Journal of clinical endocrinology and metabolism, 91 8
R. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, Gal Omry, J. Fagin, A. Shaha (2010)
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.Thyroid : official journal of the American Thyroid Association, 20 12
D. Barbaro, G. Boni, G. Meucci, U. Simi, P. Lapi, P. Orsini, C. Pasquini, A. Turco, G. Mariani (2006)
Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnantsNuclear Medicine Communications, 27
D. Barbaro, G. Boni, G. Meucci, U. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, G. Mariani (2003)
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.The Journal of clinical endocrinology and metabolism, 88 9
P. Schroeder, B. Haugen, F. Pacini, C. Reiners, M. Schlumberger, S. Sherman, D. Cooper, K. Schuff, L. Braverman, M. Skarulis, T. Davies, E. Mazzaferri, G. Daniels, D. Ross, M. Luster, M. Samuels, B. Weintraub, E. Ridgway, P. Ladenson (2006)
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.The Journal of clinical endocrinology and metabolism, 91 3
J. Jonklaas, N. Sarlis, N. Sarlis, Danielle Litofsky, K. Ain, S. Bigos, J. Brierley, D. Cooper, B. Haugen, P. Ladenson, J. Magner, J. Robbins, D. Ross, M. Skarulis, H. Maxon, S. Sherman (2006)
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.Thyroid : official journal of the American Thyroid Association, 16 12
H. Hänscheid, M. Lassmann, M. Luster, Stephen Thomas, F. Pacini, C. Ceccarelli, P. Ladenson, R. Wahl, M. Schlumberger, M. Ricard, A. Driedger, R. Kloos, S. Sherman, B. Haugen, Vincent Carrière, C. Corone, C. Reiners (2006)
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 4
B. Keizer, A. Hoekstra, M. Konijnenberg, F. vos, B. Lambert, P. Rijk, C. Lips, J. Klerk (2004)
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 45 9
Weiping Wang, S. Larson, R. Tuttle, H. Kalaigian, K. Kolbert, M. Sonenberg, R. Robbins (2001)
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.Thyroid : official journal of the American Thyroid Association, 11 12
A. Sawka, J. Brierley, R. Tsang, L. Thabane, L. Rotstein, A. Gafni, S. Straus, D. Goldstein (2008)
An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.Endocrinology and metabolism clinics of North America, 37 2
M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, G. D'Azzò, D. Meringolo, E. Ferretti, R. Sacco, F. Arturi, S. Filetti (2004)
Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.The Journal of clinical endocrinology and metabolism, 89 7
Jandee Lee, Mee Yun, K. Nam, W. Chung, E. Soh, C. Park (2010)
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.Thyroid : official journal of the American Thyroid Association, 20 2
EE Englaro HR Maxon (1992)
Radioiodine-131 therapy for well-differentiated thyroid cancer–a quantitative radiation dosimetric approach: outcome and validation in 85 patientsJ Nucl Med: Off Publ, Soc Nucl Med, 33
D. Taïeb, T. Jacob, E. Zotian, O. Mundler (2004)
Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases.Thyroid : official journal of the American Thyroid Association, 14 6
C. Pötzi, Abbas Moameni, G. Karanikas, J. Preitfellner, A. Becherer, C. Pirich, R. Dudczak (2006)
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patientsClinical Endocrinology, 65
A Hoekstra B Keizer (2004)
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancerJ Nucl Med: Off Publ, Soc Nucl Med, 45
LM Freeman AZ Rudavsky (1997)
Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormoneJ Clin Endocrinol Metab, 82
F. Pacini, E. Molinaro, M. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, A. Pinchera (2002)
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.The Journal of clinical endocrinology and metabolism, 87 9
M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, F. Pacini (2005)
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocrine-related cancer, 12 1
D. Cooper, Gerard Doherty, B. Haugen, R. Kloos, Stephanie Lee, S. Mandel, E. Mazzaferri, B. Mciver, F. Pacini, M. Schlumberger, S. Sherman, D. Steward, R. Tuttle (2009)
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid : official journal of the American Thyroid Association, 19 11
F. Pacini, F. Pacini, Pw Ladenson, M. Schlumberger, Driedger Aa, M. Luster, R. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, R. Elisei, C. Ceccarelli, A. Pinchera, Rl Wahl, S. Leboulleux, M. Ricard, J. Yoo, N. Busaidy, E. Delpassand, H. Hänscheid, R. Felbinger, M. Lassmann, C. Reiners (2006)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.The Journal of clinical endocrinology and metabolism, 91 3
C. Durante, S. Filetti (2011)
Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography.The Journal of clinical endocrinology and metabolism, 96 10
R. Robbins, S. Larson, Naina Sinha, A. Shaha, C. Divgi, K. Pentlow, R. Ghossein, R. Tuttle (2002)
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 43 11
(2011)
Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant Indian J Surg Oncol (September 2012
Abstract Since the introduction of radioiodine (RAI) for treatment of well-differentiated thyroid cancer (DTC) more than 50 years ago, prolonged periods of hypothyroidism were routinely used as part of the treatment regimen. Recombinant human TSH (rhTSH) was introduced in the 1990s as a tool to elevate the serum TSH without the need for thyroid hormone withdrawal and symptomatic hypothyroidism. After being initially approved as a diagnostic tool for use in RAI scanning and stimulated thyroglobulin testing, rhTSH was approved as an adjunct to RAI remnant ablation in patients without distant metastases in Europe in 2005 and in the US in 2007. Following successful use of rhTSH for diagnostic purposes, it has been extensively studied for use with therapeutic doses of RAI in the setting of RAI remnant ablation and is now an integral part of DCT therapy. The use of rhTSH in clinical practice in the last decade was coupled with the growing interest in an individualized, risk-stratified approach to the management of patients with DCT. While traditional treatment for DTC included surgery and RAI therapy for all patients, many more recent studies demonstrated the value of selective use of RAI only in patients who will probably benefit from treatment. This manuscript reviews the evolving role of rhTSH in the current risk adapted climate of thyroid cancer management with particular emphasis on the use of rhTSH as an aid to RAI therapy.
Indian Journal of Surgical Oncology – Springer Journals
Published: Sep 1, 2012
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.